EICHORCondition: Advanced Cancer · Breast Cancer · Advanced Solid Tumors · Sponsor: OnKure, Inc.
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| California Cancer Associates for Research and Excellence | Encinitas, California, United States | — |
| University of California San Diego UCSD | La Jolla, California, United States | — |
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | — |
| Hoag - Huntington Beach | Newport Beach, California, United States | — |
| Regents of the University of Colorado | Aurora, Colorado, United States | — |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | — |
| Stony Brook University | Stony Brook, New York, United States | — |
| SCRI Oncology Partners - Nashville | Nashville, Tennessee, United States | — |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | — |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | — |
+ 21 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06239467